[VIRTUAL] Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 MAVORIC Study

[VIRTUAL] Efficacy and Safety of Mogamulizumab by Patient Blood Classification

[VIRTUAL] Muscle-Related Adverse Events in Patients Receiving Sonidegib: Results from the 42-Month BOLT Study

[VIRTUAL] 42-Month Results on the Efficacy and Safety of Sonidegib in Patients with Aggressive and Nonaggressive Subtypes of Locally Advanced Basal Cell Carcinoma

[VIRTUAL] The Effects of Dose Reduction or Delay of Sonidegib in Locally Advanced Basal Cell Carcinoma: 42-Month Data From BOLT

[VIRTUAL] Prediction of melanoma relapse-free survival (RFS) in patients with completely resected, BRAF V600E/K–mutant, stage III cutaneous melanoma

[VIRTUAL] The Correlation Between Skin Response and Blood Involvement with Mogamulizumab

[VIRTUAL] 2-year (yr) results and biomarker analysis of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)

[VIRTUAL] Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma

[VIRTUAL] Spartalizumab + dabrafenib + trametinib in first-line treatment (tx) of BRAF V600–mutant melanoma: Clinical outcomes and biomarker analyses from COMBI-i parts 1 and 2